A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

Trial Profile

A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Prurigo nodularis
  • Focus Therapeutic Use
  • Acronyms PRISM
  • Sponsors Trevi Therapeutics
  • Most Recent Events

    • 10 Apr 2018 Status changed from planning to not yet recruiting.
    • 09 Nov 2016 New trial record
    • 13 Oct 2016 According to Trevi Therapeutics media release, this study is intended to start in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top